医学经理
百奥泰生物制药股份有限公司
- 公司规模:500-1000人
- 公司性质:合资
- 公司行业:制药/生物工程
职位信息
- 发布日期:2020-10-24
- 工作地点:广州-黄埔区
- 招聘人数:1人
- 工作经验:2年经验
- 学历要求:本科
- 职位月薪:15-75万/年
- 职位类别:生物工程/生物制药
职位描述
岗位职责:
1.上市产品临床研究方案设计及撰写,与PI沟通和讨论最后方案和实施计划;
2.管理部门内正在开展和即将开展的临床研究项目,促进临床项目的进展,保证项目的顺利进行,跟进和监督相关CRA或CRC的工作进度和工作质量;处理临床研究中遇到的问题并及时向部门经理汇报;
3.负责相关产品医药学背景知识的医学支持,包括相应医学类知识PPT制作,彩宣制作等;
4.销售团队的医药学基础知识的培训及医学答疑。
任职资格:
1.国家统招本科以上学历;
2.医学或药学相关专业;
3.2年及以上工作年限,有临床研究工作经验者优先;
4. 能熟练检索、阅读中英文文献并综述和总结相关数据;
5.能够熟练办公软件的使用。
公司介绍
百奥泰生物制药股份有限公司(股票代码:688177)秉承“创新只为生命”的理念,致力于开发新一代创新药和生物类似药,用于治疗肿瘤、自身免疫性疾病、心血管疾病以及其它危及人类生命或健康的重大疾病。公司已推动五款候选药物进入后期临床试验,其中格乐立(阿达木单抗)已在中国获批用于治疗类风湿关节炎、强直性脊柱炎、银屑病、克罗恩病和葡萄膜炎。此外,公司另有多款主攻肿瘤和自身免疫性疾病的候选药物处于不同的临床开发阶段。公司始终以患者的福祉作为首要核心价值,通过创新研发为患者提供安全、有效、可负担的优质药物,以满足亟待解决的治疗需求。欲了解更多信息,请访问公司官网或关注我们的微信公众号“百奥泰”。
Bio-Thera?Solutions, Ltd.a leading commercial-stage biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular diseases, and other serious unmet medical needs, as well as biosimilars for existing branded biologics to treat a range of cancer and autoimmune diseases. As a leader in next-generation antibody discovery and engineering, the company has advanced five candidates into late stage clinical trials, one of which, QLETLI, a biosimilar to?Humira?(adalimumab), is available to patients with rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis,?Crohn's disease or uveitis in China. In addition, the company has multiple candidates in early clinical trials and IND-enabling studies, focusing on innovative targets in immuno-oncology and autoimmune diseases.
Bio-Thera?Solutions, Ltd.a leading commercial-stage biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular diseases, and other serious unmet medical needs, as well as biosimilars for existing branded biologics to treat a range of cancer and autoimmune diseases. As a leader in next-generation antibody discovery and engineering, the company has advanced five candidates into late stage clinical trials, one of which, QLETLI, a biosimilar to?Humira?(adalimumab), is available to patients with rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis,?Crohn's disease or uveitis in China. In addition, the company has multiple candidates in early clinical trials and IND-enabling studies, focusing on innovative targets in immuno-oncology and autoimmune diseases.
联系方式
- Email:bd@bio-thera.com
- 公司地址:广州科学城开源大道11号科技企业加速器A6幢5楼 (邮编:510530)